Please use this identifier to cite or link to this item:
|Title:||Employing novel animal models in the design of clinically efficacious GPCR ligands|
|Authors:||Bradley, S. J.|
Riaz, S. A.
Tobin, Andrew B
|Publisher:||Elsevier for Current Opinion|
|Citation:||Current Opinion in Cell Biology , 2014, 27, pp. 117-125|
|Abstract:||The headline success of targeting GPCRs in human diseases has masked the fact that many GPCR drug discovery programmes fail. This is despite a substantial increase in our understanding of GPCR pharmacology that has provided an array of ligands that target both orthosteric and allosteric sites as well as ligands that show stimulus bias. From this plethora of pharmacological possibilities, can we design ligand properties that would deliver maximal clinical efficacy with lowest toxicity? This may be achieved through animal models that both validate a particular GPCR as a target as well as revealing the signalling mechanisms that underlie receptor-mediated physiological and clinical responses. In this article, we examine recent novel transgenic models being employed to address this issue.|
|Rights:||Copyright © 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ) .|
|Appears in Collections:||Published Articles, College of Medicine, Biological Sciences and Psychology|
Files in This Item:
|1-s2.0-S0955067413001890-main.pdf||Published (publisher PDF)||1.08 MB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.